B-Cell Neoplasm

hematologic malignancy

Identifier: CI-CAN-00000470
Entity page: /cancer/b-cell-neoplasm ↗
Edges: 8,293

Neighbours: 15 genes53 drugs10 trials
Drawn: 60 of 78 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
B-Cell Neoplasm approved for …APPROVED_FORderived131 of 131show fewer
← approved for	Denosumabmonoclonal antibody FDA (US) · approved · 2025-10-29 · Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.	—	approved	Multiple Myeloma	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

EZH2 Y646H TazemetostatFDA US 2020-01-238 active / 19 trials
Curatedlevel Asensitivity· support 4civicObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)Regulatoryapproved for Follicular Lymphoma (2 approval records)context: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
EZH2 A682G TazemetostatFDA US 2020-01-238 active / 19 trials
Curatedlevel Asensitivity· support 3civicObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)Regulatoryapproved for Follicular Lymphoma (2 approval records)context: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
EZH2 A692V TazemetostatFDA US 2020-01-238 active / 19 trials
Curatedlevel Asensitivity· support 3civicObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)Regulatoryapproved for Follicular Lymphoma (2 approval records)context: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
EZH2 Y646C TazemetostatFDA US 2020-01-238 active / 19 trials
Curatedlevel Asensitivity· support 3civicObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)Regulatoryapproved for Follicular Lymphoma (2 approval records)context: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
EZH2 Y646F TazemetostatFDA US 2020-01-238 active / 19 trials
Curatedlevel Asensitivity· support 3civicObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)Regulatoryapproved for Follicular Lymphoma (2 approval records)context: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
EZH2 Y646N TazemetostatFDA US 2020-01-238 active / 19 trials
Curatedlevel Asensitivity· support 3civicObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)Regulatoryapproved for Follicular Lymphoma (2 approval records)context: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
EZH2 Y646S TazemetostatFDA US 2020-01-238 active / 19 trials
Curatedlevel Asensitivity· support 3civicObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)Regulatoryapproved for Follicular Lymphoma (2 approval records)context: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
EZH2 Activating Mutation TazemetostatFDA US 2020-01-238 active / 19 trials
Curatedlevel Asensitivity· support 2civicObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)Regulatoryapproved for Follicular Lymphoma (2 approval records)context: Follicular Lymphoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

B-Cell Neoplasm altered in cohorts of …ALTERED_INderived15 of 377show all (up to 200)
← altered in cohorts of	MTRNR2L6 23 / 50 cases (46 %) · ssm · TCGA-DLBC · largest of 2 cohorts	—	—	Diffuse Large B-Cell Lymphoma	2	Observed	gdc	graph →
← altered in cohorts of	TUBB8B 23 / 50 cases (46 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	IGHV2-70 437 / 961 cases (45 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts	—	—	Multiple Myeloma	2	Observed	gdc	graph →
← altered in cohorts of	ASPM 22 / 50 cases (44 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	DSEL 22 / 50 cases (44 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	GPR149 22 / 50 cases (44 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	LAMA1 22 / 50 cases (44 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	PRSS1 22 / 50 cases (44 %) · ssm · CGCI-HTMCP-DLBCL · largest of 2 cohorts	—	—	Diffuse Large B-Cell Lymphoma	2	Observed	gdc	graph →
← altered in cohorts of	PRSS2 22 / 50 cases (44 %) · ssm · CGCI-HTMCP-DLBCL · largest of 2 cohorts	—	—	Diffuse Large B-Cell Lymphoma	2	Observed	gdc	graph →
← altered in cohorts of	ABCA13 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCYAP1 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	AHR 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	ASXL3 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	CETN1 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	CLUL1 21 / 50 cases (42 %) · ssm · TCGA-DLBC	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	gdc	graph →

B-Cell Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 286show all (up to 200)
→ investigated in trials for	Dexamethasonesmall molecule 833 trials (264 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	833	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 750 trials (240 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	750	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 667 trials (218 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	667	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 614 trials (213 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	614	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 466 trials (101 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	466	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 391 trials (103 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	391	Observed	clinicaltrials	graph →
→ investigated in trials for	Daratumumabmonoclonal antibody 226 trials (121 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	226	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 225 trials (30 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	225	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 221 trials (85 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	221	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 217 trials (86 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	217	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 206 trials (85 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	206	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 206 trials (69 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	206	Observed	clinicaltrials	graph →
→ investigated in trials for	Pomalidomidesmall molecule 203 trials (87 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	203	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall molecule 203 trials (117 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	203	Observed	clinicaltrials	graph →
→ investigated in trials for	Obinutuzumabmonoclonal antibody 186 trials (101 active) · roll-up of the cancer and its descendants	—	—	B-Cell Neoplasm	186	Observed	clinicaltrials	graph →

B-Cell Neoplasm studied in …STUDIED_INderived10 of 7,499show all (up to 200)
→ studied in	NCT00423644Phase 2 · completed A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b · condition mapped CURATED_EXACT · 7,499 trials mapped (2,445 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01414855Phase 2 · completed A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) · condition mapped CURATED_BROADER · 7,499 trials mapped (2,445 active)	—	—	B-Cell Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01559935Phase 2 · completed Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma · condition mapped CURATED_EXACT · 7,499 trials mapped (2,445 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped CURATED_EXACT · 7,499 trials mapped (2,445 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03739814Phase 2 · recruiting Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 7,499 trials mapped (2,445 active)	—	—	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1	Observed	clinicaltrials	graph →
→ studied in	NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 7,499 trials mapped (2,445 active)	—	—	ALK-Positive Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05228470Phase 2 · completed A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. · condition mapped ALIAS · 7,499 trials mapped (2,445 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05354557Phase 2 · active not recruiting Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) · condition mapped CURATED_EXACT · 7,499 trials mapped (2,445 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05621291NA · recruiting A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... · condition mapped CURATED_BROADER · 7,499 trials mapped (2,445 active)	—	—	B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05952024Phase 2 · recruiting Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL · condition mapped CURATED_BROADER · 7,499 trials mapped (2,445 active)	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →